• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Cibus Inc.

    9/23/25 4:17:55 PM ET
    $CBUS
    Agricultural Chemicals
    Industrials
    Get the next $CBUS alert in real time by email
    8-K
    false 0001705843 0001705843 2025-09-18 2025-09-18
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): September 18, 2025

     

     

    Cibus, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-38161   27-1967997

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    6455 Nancy Ridge Drive

    San Diego, CA

      92121
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (858) 450-0008

    Not Applicable

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of exchange

    on which registered

    Class A Common Stock, $0.0001 par value per share   CBUS   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.02.

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Appointment of Chief Financial Officer

    The board of directors (the “Board”) of Cibus, Inc. (“Cibus” or the “Company”) has appointed Cornelis (Carlo) Broos to serve as the Company’s Chief Financial Officer. In connection with this appointment, Cibus Global, LLC and Mr. Broos entered into an Executive Employment Agreement (the “Employment Agreement”), dated as of September 19, 2025, with a retroactive effective date of September 18, 2025.

    Mr. Broos, age 54, has served as Cibus’ Interim Chief Financial Officer since October 1, 2024. Previously, Mr. Broos served as Senior Vice President of Finance of the Company since 2024 and has significant public finance, accounting and audit experience. Prior to his current role, Mr. Broos served as the Company’s Vice President of Finance and Business Development after joining the Company in 2011. Before joining the Company, Mr. Broos served as the Head of Finance (Services) for Syngenta Europe Africa Middle East from 2008 to 2011, as CFO Netherlands and CFO Belgium for Syngenta from 2005 to 2008, as Group Controller for Advanta from 2002 to 2005 and as Audit Manager at Deloitte (Netherlands) from 1995 to 2002. Mr. Broos completed a Master of Science in Business Administration from Radboud University in 1995 and completed a post-master program in accountancy at Tilburg University in the Netherlands in 1999, becoming Registered Accountant (the equivalent of a CPA) in the Netherlands.

    Pursuant to the Employment Agreement and in connection with his appointment as Chief Financial Officer, the Board established an initial base salary for Mr. Broos of €440,000, as may be adjusted from time to time, and Mr. Broos will be eligible for a discretionary annual bonus and annual incentive equity award, in each case, as determined by the Board based on the Company’s performance and Mr. Broos’ individual performance.

    Mr. Broos is eligible to participate in employee benefit plans, such as pension, profit sharing and other retirement plans, incentive compensation plans, disability and other insurance plans, and other employee welfare plans (except for the Company’s sponsored group health insurance plan), in each case, in accordance with the employee benefit plans established by Cibus, and as may be amended from time to time in Cibus’ sole discretion.

    Mr. Broos’ employment is at-will and may be terminated at any time for any reason, except that upon termination of his employment by Mr. Broos for Good Reason or by Cibus without Cause (other than Mr. Broos’ death or Disability), in which case, Mr. Broos will be entitled to continued payments of base salary for a period of eighteen months (“Severance Benefits”). If Mr. Broos’ employment is terminated by Mr. Broos for Good Reason or by Cibus without Cause (other than Mr. Broos’ death or Disability), in each case, in connection with a Change in Control, Mr. Broos will be entitled to continued payment of base salary for a period of twenty-four months, payment of a lump sum equal to the higher of Mr. Broos’ target Annual Bonus for the year of such termination and, if termination occurs in the second half of a fiscal year, the reasonably projected Annual Bonus for the termination year, and full vesting of all of Mr. Broos’ stock options and other unvested equity (“Change in Control Severance Benefits”). The receipt of Severance Benefits and Change in Control Severance Benefits, as applicable, will be subject to delivery of customary releases contemplated by the Employment Agreement. Capitalized terms used but not defined in this paragraph have the meanings assigned in the Employment Agreement.

    Mr. Broos previously entered into the Company’s standard indemnification agreement for directors and officers, the form of which is filed with the Company’s Annual Report on Form 10-K and remains in effect with respect to Mr. Broos.

    The foregoing summary of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Employment Agreement, a copy of which is filed as Exhibit 10.1 hereto.

    Mr. Broos has no other direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, nor are any such transactions currently proposed, except that, solely for purposes of tax efficiency, approximately half of Mr. Broos’ compensation will be paid to a Belgian entity established by Mr. Broos for such purpose and wholly owned by Mr. Broos. There are no arrangements or understandings between Mr. Broos and any other persons pursuant to which Mr. Broos is being appointed as Chief Financial Officer, and there are no family relationships between Mr. Broos and any director or executive officer of the Company.

     


    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit

    Number

       Description
    10.1    Executive Employment Agreement between Cibus Global, LLC and Cornelis (Carlo) Broos, dated September 19, 2025 (effective September 18, 2025)
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, Cibus, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: September 23, 2025   CIBUS, INC.
        By:  

    /s/ Peter Beetham

        Name:   Peter Beetham, Ph.D.
        Title:   Interim Chief Executive Officer
    Get the next $CBUS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CBUS

    DatePrice TargetRatingAnalyst
    7/29/2024$25.00Buy
    Alliance Global Partners
    7/19/2024$22.00Buy
    Canaccord Genuity
    10/9/2023$25.00Buy
    H.C. Wainwright
    7/19/2023$30.00Buy
    Canaccord Genuity
    More analyst ratings

    $CBUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cibus Announces the Election of Kimberly A. Box to Board of Directors

    SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company developing and licensing advanced plant traits that enable higher yields, lower input costs, and more sustainable farming, today announced the election of Kimberly A. Box to its Board of Directors. "Kim brings to Cibus extensive leadership experience in technology and commercialization that will be invaluable as we sharpen our strategic commercialization efforts," said Mark Finn, Cibus Chairman. "Her understanding of market dynamics and experience in guiding innovation into scalable businesses will strengthen our strategic governance as we continue to drive long-term value c

    9/25/25 4:05:00 PM ET
    $CBUS
    $MGRC
    Agricultural Chemicals
    Industrials
    Diversified Commercial Services
    Consumer Discretionary

    Cibus CEO to Highlight Gene Editing's Role in Building Resilient Agriculture at UN Climate Week 2025

    SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company specializing in the development and licensing of gene-edited plant traits, today announced that Peter Beetham, Co-Founder, President, and Interim Chief Executive Officer, will participate in a featured panel during UN Climate Week 2025 in New York City. The event, titled "Investing in a Resilient Future: Innovation, Data & Capital for Energy, Food, Water, and Climate Solutions", supported by Syntax Data, will be held on Tuesday, September 23rd at Midtown Loft, New York City, with a livestream available via LinkedIn. Dr. Beetham will join leaders from the United Nations Devel

    9/22/25 12:10:00 PM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    Cibus Enters into Agreement with the Latin American Rice Hybrid Consortium to Provide Cibus' Herbicide Tolerance Trait

    Cibus and Centro Internacional de Agricultura Tropical (CIAT) have entered into an agreement to introduce Cibus' proprietary herbicide tolerance trait into elite rice germplasm for Latin America Agreement represents another significant milestone as Cibus aims to bring Latin America rice growers new solutions for advanced weed management in Rice crops SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company specializing in the development and licensing of gene-edited plant traits, today announced a material transfer agreement with Centro Internacional de Agricultura Tropical (CIAT), an organization which, in collaboration with the L

    8/28/25 7:00:00 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    $CBUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Cibus Global with a new price target

    Alliance Global Partners initiated coverage of Cibus Global with a rating of Buy and set a new price target of $25.00

    7/29/24 7:49:52 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    Canaccord Genuity resumed coverage on Cibus Global with a new price target

    Canaccord Genuity resumed coverage of Cibus Global with a rating of Buy and set a new price target of $22.00

    7/19/24 8:34:00 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    H.C. Wainwright initiated coverage on Cibus Global with a new price target

    H.C. Wainwright initiated coverage of Cibus Global with a rating of Buy and set a new price target of $25.00

    10/9/23 8:32:05 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    $CBUS
    SEC Filings

    View All

    SEC Form 8-K filed by Cibus Inc.

    8-K - Cibus, Inc. (0001705843) (Filer)

    9/23/25 4:17:55 PM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    SEC Form 8-K filed by Cibus Inc.

    8-K - Cibus, Inc. (0001705843) (Filer)

    9/16/25 4:07:49 PM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by Cibus Inc.

    SCHEDULE 13G/A - Cibus, Inc. (0001705843) (Subject)

    8/14/25 8:59:40 PM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    $CBUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Box Kimberly Ann

    4 - Cibus, Inc. (0001705843) (Issuer)

    9/26/25 9:30:15 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    New insider Box Kimberly Ann claimed no ownership of stock in the company (SEC Form 3)

    3 - Cibus, Inc. (0001705843) (Issuer)

    9/26/25 9:24:34 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    Director Riggs Rory B exercised 4,050,000 in-the-money shares at a strike of $0.00, increasing direct ownership by 38% to 14,583,307 units (SEC Form 4)

    4 - Cibus, Inc. (0001705843) (Issuer)

    6/11/25 5:11:05 PM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    $CBUS
    Leadership Updates

    Live Leadership Updates

    View All

    Cibus Announces the Election of Kimberly A. Box to Board of Directors

    SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company developing and licensing advanced plant traits that enable higher yields, lower input costs, and more sustainable farming, today announced the election of Kimberly A. Box to its Board of Directors. "Kim brings to Cibus extensive leadership experience in technology and commercialization that will be invaluable as we sharpen our strategic commercialization efforts," said Mark Finn, Cibus Chairman. "Her understanding of market dynamics and experience in guiding innovation into scalable businesses will strengthen our strategic governance as we continue to drive long-term value c

    9/25/25 4:05:00 PM ET
    $CBUS
    $MGRC
    Agricultural Chemicals
    Industrials
    Diversified Commercial Services
    Consumer Discretionary

    Cibus CEO to Highlight Gene Editing's Role in Building Resilient Agriculture at UN Climate Week 2025

    SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company specializing in the development and licensing of gene-edited plant traits, today announced that Peter Beetham, Co-Founder, President, and Interim Chief Executive Officer, will participate in a featured panel during UN Climate Week 2025 in New York City. The event, titled "Investing in a Resilient Future: Innovation, Data & Capital for Energy, Food, Water, and Climate Solutions", supported by Syntax Data, will be held on Tuesday, September 23rd at Midtown Loft, New York City, with a livestream available via LinkedIn. Dr. Beetham will join leaders from the United Nations Devel

    9/22/25 12:10:00 PM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

    EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

    1/28/25 8:00:00 AM ET
    $CBUS
    $CLLS
    $MGX
    Agricultural Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBUS
    Financials

    Live finance-specific insights

    View All

    Cibus to Report Second Quarter 2025 Financial Results on August 14, 2025 After the Market Close and Host Conference Call

    SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the company will report second quarter 2025 financial results on Thursday, August 14, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Second Quarter 2025 Results Conference Call Event Date: Thursday, August 14, 2025Time: 4:30 p.m. ETParticipant Numbers: +1-833-316-2483 (U.S.), +1-785-838-9284 (International)The conference ID "CIBUS" or 24287 will be required for en

    8/5/25 7:00:00 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    Cibus Reports First Quarter Financial Results and Provides Year-to-Date Business Update for 2025

    Rice business momentum builds with Cibus' first stacked gene edited herbicide tolerance traits, which the Company believes is an industry first; On track for 2027 targeted commercial launch of HT1 and HT3 traits with customer germplasm integration underway across multiple markets Positive regulatory decision for Cibus' Rice traits HT1 and HT3 in Ecuador; the Ministry of Agriculture and Livestock in Ecuador determined that the Company's HT1 and HT3 Rice traits are equivalent to those developed through conventional breeding Disease resistance program advances with positive Sclerotinia data for multiple modes of action against Sclerotinia in Canola; Cibus' time bound and predictable RTDS tech

    5/8/25 4:05:00 PM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    Cibus to Report First Quarter 2025 Financial Results on May 8, 2025 After the Market Close and Host Conference Call

    SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2025 financial results on Thursday, May 8, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. First Quarter 2025 Results Conference Call Event Date: Thursday, May 8, 2025Time: 4:30 p.m. ETParticipant Numbers: +1-833-316-1983 (U.S.), +1-785-838-9310 (International)The c

    4/25/25 7:00:00 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials